Insider Trading April 6, 2026

Arteris COO Executes $127,182 in Stock Sales Amid Recent Earnings Beat and High Share Price

Laurent R. Moll disposes of shares over two dates; company trades near 52-week high after Q4 2025 results exceeded estimates

By Derek Hwang AIP
Arteris COO Executes $127,182 in Stock Sales Amid Recent Earnings Beat and High Share Price
AIP

Arteris, Inc. (NASDAQ: AIP) Chief Operating Officer Laurent R. Moll sold a combined $127,182 of company shares on April 2 and April 6, with the April 2 transactions intended to cover tax liabilities tied to restricted stock units and the April 6 sale conducted under a prearranged 10b5-1 plan. The moves come as Arteris shares trade near a 52-week high and follow a quarterly report that beat revenue and EPS expectations.

Key Points

  • Arteris COO Laurent R. Moll sold a total of $127,182 in Arteris stock across transactions on April 2 and April 6.
  • April 2 sales (6,402 shares) were executed in four transactions at $17.6528 per share to cover tax liabilities from released restricted stock units; April 6 sale (1,552 shares) occurred at $18.23 under a 10b5-1 plan adopted March 12, 2025.
  • Arteris reported Q4 2025 revenue of $20.1 million and EPS of -$0.05, both better than the respective expectations of $18.55 million and -$0.07; the stock trades near its 52-week high and has returned 205% over the past year.

Arteris, Inc. (NASDAQ: AIP) Chief Operating Officer Laurent R. Moll completed two sets of stock sales in early April totaling $127,182.

On April 2, Moll sold 6,402 shares of Arteris common stock across four separate transactions, each executed at a per-share price of $17.6528, representing aggregate proceeds of $98,890. Those April 2 sales were made specifically to satisfy tax obligations arising from the release of restricted stock units.

Four days later, on April 6, Moll sold an additional 1,552 shares at $18.23 per share, generating $28,292. The April 6 transaction was carried out under a prearranged 10b5-1 trading plan that Moll adopted on March 12, 2025.

After these transactions, Moll is recorded as holding 280,972 shares of Arteris directly.


Market context for the insider activity is notable: Arteris shares have been trading close to a 52-week high of $19.85 and have delivered a 205% return over the past year. An analysis by InvestingPro referenced with the company indicates that the stock is trading above its Fair Value, a valuation signal the analysis suggests investors should weigh alongside the company’s recent performance and momentum.

Those performance signals were reinforced by Arteris’s fourth-quarter 2025 results, which topped consensus expectations. The company reported revenue of $20.1 million, exceeding the projected $18.55 million. Reported earnings per share were -$0.05, which was better than the anticipated -$0.07. Analysts noted that the quarter surpassed market forecasts on both top-line and EPS measures, drawing attention from market participants.

This report focuses strictly on the disclosed insider transactions, the stated rationale for the April 2 sales, the fact that the April 6 sale occurred under a March 12, 2025 10b5-1 plan, and the company’s reported quarter. It does not speculate on motives beyond the stated tax-coverage purpose or on likely future stock performance.


Note on information scope: The figures and dates in this article are taken from the company filings and the disclosed trading plan details. Contextual valuation commentary referenced the InvestingPro analysis as presented alongside the company’s trading and earnings information.

Risks

  • Insider sales may be interpreted by market participants in different ways; the April 2 sale was disclosed as tax-related and the April 6 sale under a 10b5-1 plan, but interpretations can still affect investor sentiment - affecting equity markets and semiconductor-related stocks.
  • InvestingPro analysis cited indicates the stock is trading above its Fair Value, which introduces valuation risk for existing or prospective investors as price momentum may not align with assessed fair value - relevant to equity and technology sectors.
  • While the company beat Q4 2025 revenue and EPS estimates, earnings and outlooks remain subject to future operational and market variability; these uncertainties can influence valuation and capital markets activity in the semiconductor intellectual property sector.

More from Insider Trading

Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026 Power Integrations VP Sells 313 Shares to Cover Tax Bill; Stock Up 45% YTD Apr 6, 2026 Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026